Jefferies has reiterated its Buy rating for Gilead Sciences (GILD.US) and maintained a price target of $180. The content of the article is not availab...
Bullish
Gilead Sciences has signed a $139.8 million deal to source active pharmaceutical ingredients (APIs) from South Korea's Yuhan, expanding on their exist...
Neutral
Gilead Sciences has received a positive opinion from the CHMP for Trodelvy (sacituzumab govitecan-hziy) as a monotherapy for first-line metastatic tri...
Neutral
Keudell Morrison Wealth Management has acquired a new stake of 16,022 shares in Gilead Sciences, valued at approximately $1.97 million during the four...
Neutral
PNC Financial Services Group Inc. increased its stake in Gilead Sciences, Inc. by 12.6% during the fourth quarter, bringing its total holdings to 474,...
Bullish
Northwestern Mutual Wealth Management Co. increased its stake in Gilead Sciences, Inc. by 14.9%, purchasing an additional 13,252 shares, bringing thei...
Neutral
Gilead Sciences and its company Kite will present over 25 abstracts at the 2026 ASCO Annual Meeting and EHA Congress, showcasing momentum in antibody-...
Bullish
Moderna's stock has surged significantly year-to-date, but the article argues that its fundamentals remain weak with projected revenue collapse and ca...
Bullish
Gilead Sciences Inc. has renewed its five-year collaboration with the World Health Organization (WHO) to combat visceral leishmaniasis (VL), also know...
Gilead Sciences has completed its acquisition of Tubulis GmbH for $3.15 billion upfront and up to $1.85 billion in contingent milestone payments. This...
Bullish
Gilead Sciences and the World Health Organization (WHO) have announced an expanded five-year collaboration to eliminate visceral leishmaniasis (VL), a...
Bullish
Leonteq Securities AG has initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) by purchasing over 16,000 shares valued at approximately $1....
Gilead Sciences and the World Health Organization (WHO) have renewed their collaboration for another five years to accelerate the elimination of visce...
Maxim has upgraded Gilead Sciences (GILD) from a "Hold" rating to a "Buy" rating, setting a new price target of $165. The article also briefly mention...
Neutral
Morgan Stanley has lowered its price target for Gilead Sciences (GILD) to $168 from $175, while maintaining an Overweight rating following the company...
Bullish
Jag Capital Management LLC has acquired a new stake of 112,101 shares, valued at approximately $13.8 million, in Gilead Sciences, making it their 27th...
Neutral
Mitsubishi UFJ Asset Management UK Ltd. reduced its stake in Gilead Sciences by 32.1% in the last quarter of 2025, selling 9,000 shares and retaining ...
Bullish
Fideuram Intesa Sanpaolo Private Banking S.P.A. has acquired a new stake of 413,875 shares in Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximat...
Neutral
Atle Fund Management AB significantly reduced its stake in Gilead Sciences, Inc. by 35% in the fourth quarter, selling 27,373 shares and retaining 50,...
Bullish
ProShare Advisors LLC significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by acquiring an additional 623,752 shares, bringing its...